Ms. Drexler is a serial entrepreneur with expertise in the fields of digital health, medical devices, and diagnostics.
Ms. Drexler serves on the boards of two other public companies, Resmed, Inc., where she serves on the compensation and nominating and governance committees, and Outset Medical Inc., where she chairs the compensation committee and serves on the nominating and governance committee.
Ms. Drexler is also on the board of three private companies: Bone Health Technologies Inc., a medtech company focused on treating osteoporosis and its precursor, osteopenia, VIDA Diagnostics Inc., an artificial intelligence powered lung imaging solutions company, and Tivic Health Systems, Inc., a bioelectric medicine company focused on relief of congestion and sinus pain. Ms. Drexler also acts as a senior strategic advisor for other early-stage companies, and spent 11 years on the board of the Keller Center for Innovation in Engineering Education at Princeton University. Ms. Drexler is an active mentor and advisor with Astia, a global nonprofit that supports high-potential female founders. She is a founding member of Astia Angels, a network of individual investors who fund such founders, and a lead mentor with StartX, the Stanford University incubator. She is also on the Life Science and Women’s Health Councils for Springboard, an accelerator for women-led technology-oriented companies.
Ms. Drexler graduated magna cum laude with a B.S.E. in Chemical Engineering from Princeton University, and earned an MBA with honors from the Stanford University Graduate School of Business.
Dr. Evans AM is an experienced leader and CEO with a broad technical background across multiple industry sectors including medical technology, manufacturing, power generation and distribution, and technical regulation and standards.
Dr. Evans is currently the CEO of Engineers Australia, the Chair of Building 4.0 CRC, and the Director at GME Pty Ltd. Prior to her role with Engineers Australia, Dr. Evans was the CEO of Standards Australia. Dr. Evans has previously held positions in innovation initiatives, including as Chair of MTPConnect (the Industry Growth Center for Medical Technologies and Pharmaceuticals) and was a member of the Industry 4.0 Advanced Manufacturing Forum Leadership group. She has also held various senior engineering roles, including at Cochlear and GE Healthcare.
Dr. Evans has been recognized as one of Australia’s 100 most influential engineers and recognized as a 100 Women of Influence.
Dr. Evans holds a BE (Honors I) and a Ph.D. in Electrical Engineering from the University of Wollongong . She also has an Honorary Doctorate from Swinburne University and is an Honorary Fellow of the University of Wollongong and Engineers Australia and a Fellow of the Australian Academy of Technological Sciences and Engineering.
Bronwyn Evans, Ph.D. AM
Mr. McCutcheon has served as President and CEO of EBR since June 2019 and is responsible for the overall management and strategic direction of EBR.
Mr. McCutcheon has over 35 years of experience in sales, marketing, and management of medical device companies. Prior to joining EBR, Mr. McCutcheon was the President and CEO of Ceterix Orthopaedics, Inc. for nine years from 2010 to 2019. He also held CEO roles at Ventus Medical, Inc. (2009-2010) and Emphasys Medical, Inc. (2000-2009).
Mr. McCutcheon holds a B.A. in Economics and Psychology from the University of California, Los Angeles and an MBA from the UCLA Anderson Graduate School of Management.
President, Chief Executive Officer, and Executive Director
Mr. Moody has served as a Director of EBR since 2017.
Mr. Moody currently serves as Medical Device Partner at M.H. Carnegie & Co. (since October 2013), where he makes investments in medical device companies. He has also served since January 2010 as President of TM Strategic Advisors LLC, a management consultancy. Mr. Moody was previously a General Partner at Frazier Healthcare Ventures, a large U.S. based private equity and venture capital firm.
Mr. Moody is currently a Director of electroCore, Inc., Australian Medtech Services Pty Ltd., Cardiac Dimensions Pty Ltd., Renew Medical Pty Ltd., Serene Medical Pty Limited, The Brain Protection Company Pty Ltd., and CurvaFix, Inc. Mr. Moody also serves on the board of Angel Flight West, a not-for-profit that provides free air transport for patients requiring long distance travel for medical treatment. Mr. Moody was a Director of Simplify Medical Pty Ltd. at the time of its sale to NuVasive, Inc..
Mr. Moody holds a B.Eng. from the University of Southern Queensland, and a M.S. in Management from the Massachusetts Institute of Technology (Sloan School).
Dr. Nave has served as a Director of EBR since 2017.
Dr. Nave is a Founder and Managing Director of Brandon Capital Partners and the CEO of the Medical Research Commercialisation Fund. Dr. Nave previously served as the Director of Commercialisation at the Baker Heart Research Institute.
Dr. Nave is currently a Director of The Australian Investment Council, Azura Ophthalmics, Inc., Certa Therapeutics Pty Ltd., Global Kinetics Corporation Ltd., OccuRx Pty Ltd., Osprey Medical Inc., PolyActiva Pty Ltd. and Que Oncology, Inc. Dr. Nave was Chairperson of Fibrotech Therapeutics Pty Ltd. at the time of its successful sale to Shire Plc and a Director of Spinifex Pharmaceuticals, Inc. at the time of its sale to Novartis International AG.
Dr. Nave holds a B.Sc. (Honours) and a Ph.D. in Endocrinology and Physiology from the University of Melbourne. Dr. Nave is also a member of the Australian Investment Council.
Christopher Nave, Ph.D
Dr. Steinhaus retired in 2019 as Vice President and General Manager of the Heart Failure Business for the Cardiac Rhythm and Heart Failure Division at Medtronic plc.
Dr. Steinhaus joined Medtronic in 2005, after 20 years of cardiology (electrophysiology) practice. Dr. Steinhaus’ responsibilities at Medtronic included bringing the physician voice to CRHF, identifying future opportunities in new product development, and serving as a liaison to government agencies, professional societies and medical groups.
Dr. Steinhaus has been closely associated with research and academia, performing extensive clinical studies in implantable cardiac devices and leads. He served as Chair of the Department of Cardiology, and Director of the Electrophysiology Department at the Mid America Heart Institute and St. Luke’s Hospital and Director of the Electrophysiology Fellowship Program at the University of Missouri at Kansas City School of Medicine, and has instructed students in medicine since 1982. Since leaving Medtronic, he has served as a consultant and board member to multiple established and early stage medical device companies. He is currently the Executive Chairman of the board of Enopace Biomedical Ltd., a company which produces therapeutic neuromodulation devices for the treatment of heart failure.
A 1973 magna cum laude graduate of Harvard College, Dr. Steinhaus received his medical doctorate from Harvard Medical School as part of the Harvard‑M.I.T. program in Health Sciences and Technology, with AOA honors.
David Steinhaus, MD
Mr. Will served as the CEO of the Company from 2011 until 2019, and has served in the role of Executive Chair since 2019.
Mr. Will is a seasoned executive with extensive experience founding, funding, operating, and selling medical device companies. In addition to his role with the company, Mr. Will currently serves as Chair of the boards of Fractyl Health, Inc. and SetPoint Medical Corporation, and a Director of Fogarty Innovation, a not-for-profit institute promoting innovation in medical technology founded by Dr. Thomas J. Fogarty.
Previously, as Chair of Ardian, Inc., Mr. Will led negotiations of the company’s acquisition by Medtronic Inc. for over $800 million. Mr. Will was also founding Managing Director of Split Rock Partners’ Silicon Valley office, focusing on therapeutic medical devices, having joined Split Rock Partners’ predecessor entity St. Paul Venture Capital (SPVC) in 2002. Mr. Will was Founder, Chair and CEO of The Foundry, co-founding 11 companies there, including Ardian, Evalve, Inc. (acquired by Abbott Laboratories for $450 million) and Concentric Medical Inc. (acquired by Stryker Corp. for $135 million).
Mr. Will is an inventor on more than 30 issued patents, is a University of Maryland Distinguished Alumnus and a recipient of the ASTIA/Deloitte Excellence in Mentoring Women Executives Award. He served on the MIT Entrepreneurship Center Shareholders’ Board and the University of Maryland President’s Committee on Innovation and Entrepreneurship.
Mr. Will earned a B.S. in Zoology from the University of Maryland and his M.S. in Management from the Massachusetts Institute of Technology.